ESR1 and breast cancer: Eighty percent of all newly diagnosed cases of breast cancer are ERα positive,194 as ERα is considered the major regulator that transduces estrogen signaling in the female reproductive tract and mammary glands.216 The current treatment standard is fulvestrant which acts through selectively degrading the estrogen receptor for ER+ metastatic breast cancer.